Gilead Sciences Inc. doesn’t have to face a fired employee’s claim that its response to a colleague’s false sexual harassment ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of Goldman Sachs’ top healthcare stock picks. On July 10, the company announced it ...

The World Health Organisation (WHO) has included Gilead Sciences' twice-yearly formulation of lenacapavir for pre-exposure ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Cheap Stocks to Buy According to Billionaire Ray Dalio. Bridgewater ...

Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Gilead researchers and collaborators will present new Phase 3 ...

Shares of Gilead Sciences Inc. slipped 4.28% to $109.64 Friday, on what proved to be an all-around dismal trading session for ...

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Gilead Sciences, Inc. (“Gilead” or “ ...

WHO’s director general described the policy guidelines for Gilead’s twice-yearly drug as the “next best thing” in the absence of a vaccine.

See the latest Gilead Sciences GILD stock price (NASDAQ: GILD), related news, valuation, dividends and more to help you make your investing decisions.

Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. (“Gilead” or the “Company”) (NASDAQ: GILD). Such investors are ...

Gilead Sciences Inc. closed 5.60% below its 52-week high of $119.96, which the company achieved on March 10th.